drugset / Trial / NCT03731221
Pectoral Fascial Plane and Serratus Anterior Plane Blocks With Bupivacaine v. Liposomal Bupivacaine
RandomizedParallel-groupDouble-blindTreatment
Summary
Patients will be randomized the day of surgery upon presentation to the operating room to either a treatment group (PECSII/SAP blocks with bupivacaine HCl plus liposomal bupivacaine) or a control group (PECSII/SAP blocks with bupivacaine HCl plus preservative free normal saline) using secure web-based randomization. Assignments will be based on computer-generated code. Clinicians will not be blinded to the intervention, but all outcomes will be assessed by research personnel who are blinded to the group assignment.
Timeline
- Start
- 2018-11-01
- Primary completion
- 2024-09-19
- Completion
- 2024-09-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupivacaine | Other / unclassified | 2.5 mg/kg | Other |
| Subject | Bupivacaine | Other / unclassified | 150 mg | Other |
| Subject | Bupivacaine | Other / unclassified | 266 mg | Other |
Indications
No indication recorded.